Enliven Therapeutics (ELVN) Accumulated Expenses (2019 - 2026)

Enliven Therapeutics has disclosed Accumulated Expenses across 8 years of filings, most recently posting $9.8 million for Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $9.8 million, down 20.65% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.8 million (down 20.65% YoY), and the FY2025 annual result was $14.4 million, up 212.63% from the prior year.
• Accumulated Expenses came in at $9.8 million for Q1 2026 at Enliven Therapeutics, down from $14.4 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $14.4 million in Q4 2025 to a low of $1.0 million in Q1 2023.
• The 5-year median for Accumulated Expenses is $6.3 million (2022), against an average of $7.1 million.
• Across the five-year window, Accumulated Expenses plunged 78.51% in 2023 and jumped 1085.36% in 2024, its largest moves.
• Enliven Therapeutics' Accumulated Expenses stood at $6.3 million in 2022, then plunged by 46.98% to $3.3 million in 2023, then soared by 38.49% to $4.6 million in 2024, then soared by 212.63% to $14.4 million in 2025, then tumbled by 31.66% to $9.8 million in 2026.
• The last three Accumulated Expenses figures came in at $9.8 million (Q1 2026), $14.4 million (Q4 2025), and $13.2 million (Q3 2025), per Business Quant data.